

**Table 1. Baseline characteristics of the POAF group and non-POAF group**

	<b>POAF (N=16)</b>	<b>non-POAF (N=206)</b>	<b>P value</b>
Age (y)	76	76	0.679
BMI	23	23	0.813
Female sex, n (%)	2 (13)	51 (25)	0.369
sBP (mmHg)	133	139	0.170
HR (/min)	78	72	0.078
Bisoprolol patch, n (%)	4 (25)	108 (52)	0.040
PMI, n (%)	9 (56)	80 (39)	0.193
RCRI > 2, n (%)	15(94)	170(83)	0.483
DOT ≥ 250min	13(81)	92(45)	0.009
Surgical specialty, n (%)			
General	4(25)	52(25)	1.000
Thoracic	11(69)	85(41)	0.119
Vascular	1(6)	43(21)	0.206
Blood test			
Hb (g/dL)	13.9	12.5	0.006
Cre (mg/dL)	0.95	1.01	0.552
eGFR (mL/min/1.73m <sup>2</sup> )	60.4	59.1	0.802
CRP (mg/dL)	0.58	0.81	0.492
HbA1c (%)	6.6	6.3	0.175
Echocardiography			
Left atrial dimension (mm)	36	37	0.326
Ejection fraction (%)	66	65	0.574
Asynergy, n (%)	3 (19)	22 (11)	0.400
E/e'	11	13	0.166
TRPG (mmHg)	23	24	0.804
Respiratory function test			
Vital capacity – L	3.0	2.9	0.587
Forced expiratory volume 1.0 second - %	69	74	0.113
Past history			
Ischemic heart disease, n (%)	8 (50)	122 (59)	0.600
Heart failure, n (%)	4 (25)	52 (25)	1.000
Diabetes mellitus, n (%)	9 (56)	93 (45)	0.443
Dyslipidemia, n (%)	12 (75)	106 (51)	0.116
Hyperuricemia, n (%)	3 (19)	34 (17)	0.736
Myocardial infarction, n (%)	1 (6)	7 (3)	0.457
Peripheral artery disease, n (%)	2 (13)	16 (8)	0.626
Asthma, n (%)	0	4 (2)	1.000
PCI, n (%)	2 (13)	31 (15)	1.000
CABG, n (%)	0	5 (2)	1.000
Medication, n (%)			
CCB	11 (69)	121 (59)	0.599
ACE-I	0	19 (9)	0.372
ARB	7(44)	99(48)	0.800
MRA	0	5(2)	1.000

<b>Diuretics</b>	<b>2(13)</b>	<b>24(12)</b>	<b>1.000</b>
<b>Alfa blocker</b>	<b>0</b>	<b>8(4)</b>	<b>1.000</b>
<b>Digitalis</b>	<b>0</b>	<b>2(1)</b>	<b>1.000</b>
<b>Statin</b>	<b>8(50)</b>	<b>82(40)</b>	<b>0.440</b>
<b>DPP4-I</b>	<b>5(31)</b>	<b>51(25)</b>	<b>0.557</b>
<b>SGLT-2</b>	<b>0</b>	<b>5(2)</b>	<b>1.000</b>
<b>Insulin</b>	<b>2 (13)</b>	<b>32 (16)</b>	<b>1.000</b>

---

POAF, postoperative atrial fibrillation; BMI, body mass index; sBP, systolic blood pressure; HR, heart rate; PMI, perioperative myocardial injury; RCRI, revised cardiac risk index; DOT, duration of surgery time; TRPG, transtricuspid pressure gradient; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensinIIreceptor blocker; MRA, mineralocorticoid receptor antagonist; DPP4-I, dipeptidyl peptidase-4 inhibitor; SGLT-2, sodium glucose cotransporter2 inhibitor